Clinical Trials Logo

Keratosis clinical trials

View clinical trials related to Keratosis.

Filter by:

NCT ID: NCT01600014 Completed - Actinic Keratosis Clinical Trials

Ingenol Mebutate Gel, 0.015% Repeat Use for Multiple Actinic Keratoses on Face and Scalp

Start date: May 2012
Phase: Phase 3
Study type: Interventional

The purpose of the study is to demonstrate that ingenol mebutate gel is efficacious in treating Actinic Keratoses (AKs) present 8 weeks after initial field treatment or emerging in a previously cleared field.

NCT ID: NCT01583816 Completed - Actinic Keratosis Clinical Trials

Dose-finding, Safety, Efficacy Trial of Topical Resiquimod in Patients With Multiple Actinic Keratosis Lesions

Start date: May 2012
Phase: Phase 2
Study type: Interventional

A Dose-Finding Study of Resiquimod Evaluating Safety and Efficacy in Patients with Multiple Actinic Keratosis Lesions

NCT ID: NCT01571336 Completed - Actinic Keratosis Clinical Trials

Photodynamic Therapy of Actinic Keratoses With Alacare®

Start date: April 2012
Phase: N/A
Study type: Observational

This study aims to collect data on the frequency of SCCs in the Alacare®-treated area during an interval of two years after Alacare®-PDT.

NCT ID: NCT01541553 Completed - Actinic Keratosis Clinical Trials

A Sequential Treatment Regimen of Cryotherapy and Picato® for the Treatment of Actinic Keratosis on the Face and Scalp

Start date: March 2012
Phase: Phase 3
Study type: Interventional

The purpose of this trial is to compare the rate of complete clearance of actinic keratosis (AK) using sequential cryotherapy and field treatment with PEP005 Gel compared to cryotherapy alone.

NCT ID: NCT01541228 Completed - Actinic Keratosis Clinical Trials

Photodynamic Treatment of Actinic Keratoses With Different Light Doses

Start date: April 2010
Phase: N/A
Study type: Interventional

Aim of the study: To evaluate clinical effectiveness of two different light doses when treating actinic keratoses with photodynamic therapy with 20% 5-aminolevulinic acid.

NCT ID: NCT01516515 Completed - Actinic Keratosis Clinical Trials

Efficacy and Safety Phase II Study of SR-T100 to Treat Actinic Keratosis

Start date: February 2013
Phase: Phase 2
Study type: Interventional

This Phase II study is to evaluate the efficacy of SR-T100 gel with 2.3% of SM in Solanum undatum plant extract in patient with Actinic Keratosis (AK).

NCT ID: NCT01502020 Completed - Actinic Keratoses Clinical Trials

A Bioequivalence Study With Clinical Endpoints Comparing Generic Imiquimod Cream, 3.75% and Zyclara™ (Imiquimod) Cream, 3.75% in Subjects With Actinic Keratoses

Start date: February 2011
Phase: N/A
Study type: Interventional

Zyclara™ (imiquimod) Cream, 3.75% is approved by the FDA for the treatment of actinic keratoses on the full face or balding scalp. Zyclara is applied once daily for two, 2-week treatment cycles separated by a 2-week no treatment applied interval. A generic imiquimod cream, 3.75% has been developed by Actavis Mid-Atlantic LLC for the topical treatment of clinically typical, visible or palpable actinic keratoses (AK) of the full face or balding scalp. The current clinical study is designed to evaluate the therapeutic equivalence of this formulation with the currently marketed Zyclara™ (imiquimod) cream, 3.75% formulation (Graceway Pharmaceuticals LLC).

NCT ID: NCT01493921 Completed - Actinic Keratosis Clinical Trials

Efficacy Study & Safety Evaluation of SR-T100 Gel in Actinic Keratosis Treatment

Start date: October 2011
Phase: Phase 3
Study type: Interventional

Studies of SR-T100 gel and its clinical relevance in the treatment of AK, providing adequate measured outcomes for skin lesion treatment. In addition to the high complete response rate (90.0%) as compared with the conventional therapy, the most significant result was that no undesirable side effects were associated with the use of SR-T100 gel. The result also shows approximately 80% of study subjects had a complete response in phase II clinical trial conducted in Taiwan; hence, result from our study model suggested SR-T100 gel offers beneficial therapeutic values in treatment of AK is harmless to the skin as well as high tolerance level displayed by majority of patients.

NCT ID: NCT01475955 Completed - Actinic Keratosis Clinical Trials

Short-incubation Levulan Photodynamic Therapy Versus Vehicle for Face/Scalp Actinic Keratosis (AK)

Start date: December 2011
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine if Levulan Photodynamic Therapy (PDT) is safe and effective in the treatment of actinic keratosis when applied to broad areas on the face and scalp for 1, 2 and 3 hours.

NCT ID: NCT01475071 Completed - Actinic Keratoses Clinical Trials

Intra-individual Comparison of Efficacy and Safety of Metvix® Natural Daylight Photodynamic Therapy Versus Conventional Metvix® Photodynamic Therapy in Subject With Mild Actinic Keratoses

CoMet
Start date: March 2012
Phase: Phase 3
Study type: Interventional

The main objective of this study is to compare efficacy and safety of Metvix® natural daylight photodynamic therapy with those of Metvix® conventional photodynamic therapy with Aktilite™ lamp in subjects with mild actinic keratoses (intra-individual comparison).